ALPS MEDICAL BREAKTHROUGHS ALPS MEDICAL ETF News

In the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which well-heeled blue-chip pharmaceutical companies w

Many investors hoping for a resurgence by biotech stocks have hitched their wagons to the Federal Reserve lowering interest rates. That's a practical bet because biotech is a rate-sensitive industry.

Biotech stocks and exchange traded funds have endured a lengthy rough patch. And the pain has been particularly acute for small- and mid-cap fare.

With lower interest rates now in sight and renewed confidence in the stock market, deal making activity should pick up in 2024 after a slow couple of years. For retail investors, this could lead to ne

Wall Street's newfound bullishness on small caps reflects a notable shift in market dynamics, with several analysts predicting continued growth.

Many of us were prepping for year-end (or on vacation in Belize, in my case) in December. However, index providers were hard at work to ensure certain ETFs fully reflected the investment criteria advi

Wall Street sizzled in December, with all three major indices touching a series of new highs.

With the year drawing to a closer, investors may be on the lookout for a strategy or idea that has some momentum. In a notable turnaround from earlier this year, biotech looks to be one such area to c

To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.

It's been a complicated year for tech firms outside those “Magnificent Seven” names that have, to some degree, outgrown a simple “tech” distinction. High interest rates have taken a toll on te

The S&P 500 hit a new high for the year last week after the November jobs report and University of Michigan consumer survey data indicated a resilient economy and cooling inflation, triggering bets on

Tech has been a big driver of market resilience this year, with AI specifically boosting earnings for all kinds of companies. That said, technology isn't just moving forward in software.

Biotechnology is certainly on the list, if not at the top, of high-growth industries in dire need of a rebound. Following enthusiasm for COVID-19 vaccines in late 2020 and part of 2021, biotechnology

After a downbeat September, October too remained volatile for Wall Street due to higher rates.

Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users